NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Financial Flexibility Index
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Financial Flexibility Index of -0.56x as of September 2025. Free cash flow of $-32.73 Million (operating CF $-32.77 Million minus capex $42.00K) represents -1% of total liabilities ($58.36 Million). Check NAMS PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. See how liquid is NewAmsterdam Pharma Company N.V. Ordinar's working capital to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Year-by-year free cash flow to debt coverage for NewAmsterdam Pharma Company N.V. Ordinary Shares. For the full company profile including market capitalisation, see market value of NewAmsterdam Pharma Company N.V. Ordinar.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.47x | $-157.89 Million | $-158.56 Million | $107.12 Million | ▲ +38.7% |
| 2023 | -2.41x | $-141.19 Million | $-141.22 Million | $58.70 Million | ▼ -1170.0% |
| 2022 | 0.22x | $10.89 Million | $10.66 Million | $48.43 Million | ▲ +108.7% |
| 2021 | -2.60x | $-29.49 Million | $-29.51 Million | $11.36 Million | ▼ -339.5% |
| 2020 | -0.59x | $-7.33 Million | $-7.34 Million | $12.41 Million | — |